Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis;Grundversorgung und Medikamentöse Behandlung von Patienten mit Toxisch Epidermaler Nekrolyse

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue 5, 2010, Pages 341-346

  Hanken, Imke ^a   Schimmer, Melanie ^a   Sander, Christian A ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Basic measures; Corticosteroids; Epidermal sloughing; Immunoglobulins; Lyell syndrome; Toxic epidermal necrolysis TEN; Unwelcome drug reaction

Indexed keywords

ALLOPURINOL; AMOCLAV; AMOXICILLIN PLUS CLAVULANIC ACID; BUPRENORPHINE; CIPROFLOXACIN; CORTICOSTEROID; COTRIM FORTE; COTRIMOXAZOL; COTRIMOXAZOLE; DERMATOPSALBE; DIMETINDENE; DOXYCYCLINE; ERYTHROMYCIN; FEXOFENADINE; HYDROXOCOBALAMIN; LIDOCAINE; MEDIVITAN N; OMEP; OMEPRAZOLE; PHENYTOIN; PREDNISOLONE; PREDNISOLONE SODIUM SUCCINATE; PREDNISONE; PYRIDOXINE; RANITIC; RANITIDINE; SULFONAMIDE; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; ANTIGOUT AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; DRUG COMBINATION; FOLIC ACID;

ADULT; AGED; ARTICLE; ASSISTED CIRCULATION; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOTHERMIA; INCIDENCE; MALE; PROTEUS MIRABILIS; SKIN EXFOLIATION; SMEAR; STAPHYLOCOCCUS AUREUS; SYSTEMIC THERAPY; TOXIC EPIDERMAL NECROLYSIS; BACTERIAL INFECTIONS; CASE REPORT; DRUG COMBINATION; MIDDLE AGED; MORTALITY; STEVENS-JOHNSON SYNDROME; SUPERINFECTION; SURVIVAL RATE; TOXICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; BACTERIAL INFECTIONS; CIPROFLOXACIN; DRUG COMBINATIONS; FEMALE; FOLIC ACID; GOUT SUPPRESSANTS; HUMANS; HYDROXOCOBALAMIN; LIDOCAINE; MALE; MIDDLE AGED; PHENYTOIN; PREDNISONE; PYRIDOXINE; STEVENS-JOHNSON SYNDROME; SUPERINFECTION; SURVIVAL RATE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 77951781323     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07289.x     Document Type: Article

References (25)

1. Rzany B, Mockenhaupt M, Baur S, Shröder W, Stocker U, Mueller J, Holländer N, Bruppacher R, Schöpf E. Epidemiology of erythema exsudativum multiforme majus, Stevens- Johnson syndrome and toxic epidermal necrolysis in Germany (1990- 1992). Structure and results of a population- based registry. J Clin Epidemiol 1996 : 49 : 769 773.
2. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severitiy-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000 115 : 149 153.
3. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R, JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens- Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008 9 : 1617 1622.
4. Roujeau JC, Kelly JP, Naldi L. Medication use and the risk of Steven Johnson syndrome and toxic epidermal necrolysis. N Engl J Med 1995 333 : 1600 1609.
5. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavnick JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC. Allopurinol ist the most common cause of Stevens Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. JAAD 2008 58 : 25 32.
6. Anhalt G, Snelling CF. Toxic epidermal necrolysis. Plast Reconstr Surg 1978 61 : 905 910.
7. Bjornberg A. Fifteen cases of toxic epidermal necrolysis. Acta Dermatol 1973 15 : 149 152.
8. Criton S, Devi K, Sridevi PK, Asokan PV. Toxic epidermal necrolysis- a retrospective study. Int J Dermatol 1997 36 : 923 925.
9. Stables GI, Lever RS. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol 1997 128 : 357.
10. Herndon D. Toxic epidermal necrolysis: A systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995 180 : 340 342.
11. Kelemen JJ, Cioffi W, McManus W, Mason A, Pruritt B. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995 18 : 273 278.
12. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. JAAD 2007 56 : 181 200.
13. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 282 : 490 493.
14. Trent JT, Halem M, French LE, Kerdel F. Toxic epidermal necrolysis and intravenous immunoglobulin: A review. Seminars in cutaneous medicine and surgery 2006 25 : 91 3.
15. Prins FA, Kerdel FA, Padilla S. Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobu-lins. Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003 139 : 26 32.
16. Trent JT, Kirsner RS, Romanelli P. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 2003 140 : 890 892.
17. Al-Mutairi N, Arun J, Osama NE. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004 43 : 847 851.
18. Campione E, Marulli GC, Carrozzo AM. High dose intravenous immunoglobulin for severe drug reactions: Efficacy in toxic epidermal necrolysis. Acta Derm Venerol 2003 83 : 430 432.
19. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Steven Johnson syndrome and toxic epidermal necrolysis. Seven cases and review of the literature. Pediatrics 2003 112 : 1430 1436.
20. Tristani-Firouzi P, Petersen MJ, Saffle JR. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. JAAD 2002 47 : 548 552.
21. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003 139 : 33 6.
22. Brown KM, Silver GM, Halerz M. Toxic epidermal necrolysis. Does immunoglobulin make a difference? J Burn Care Rehabil 2004 25 : 81 8.
23. Frangogiannis NG, Boridy I, Mazahr M, Mathew R, Gangopadhyay S, Cate T. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996 89 : 1001 1003.
24. Paquet P und Pierad GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999 198 : 198 200.
25. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor alpha antibodies (Infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002 146 : 707 709.